Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 2Neuroblastoma 2Meningioma 2Medulloblastoma 2Small Cell Lung Carcinoma 1Recurrence 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Hydroxyurea 7Bevacizumab 7Everolimus 6lutetium Lu 177 dotatate 4Magnetic Resonance Spectroscopy 4pembrolizumab 3abemaciclib 3Sunitinib 3Imatinib Mesylate 3vistusertib 2gallium Ga 68 dotatate 2arginyllysine 2aldesleukin 2Whole Body Imaging 2Specimen Handling 2Radiotherapy 2Octreotide 2Nivolumab 2Cyclophosphamide 2Amino Acids 290Y-octreotide, DOTA-Tyr(3)- 2vatalanib 1tozuleristide 1sargramostim 1regorafenib 1pasireotide 1neratinib 1fludarabine phosphate 1fludarabine 1dexamethasone acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Meningioma × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT03013387 2017-08-25

Dosimetry Guided PRRT With 90Y-DOTATOC

University of Iowa

Phase 2 Withdrawn
CNS

Medulloblastoma, Meningioma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡